Sharma Cheshta, Hagen Ferry, Moroti Ruxandra, Meis Jacques F, Chowdhary Anuradha
Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India.
Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
J Glob Antimicrob Resist. 2015 Jun;3(2):69-74. doi: 10.1016/j.jgar.2015.01.005. Epub 2015 Feb 14.
Triazole resistance in Aspergillus fumigatus develops in patients with chronic lung diseases receiving long-term azole therapy or by environmental selection of resistant A. fumigatus. Here we report for the first time the isolation of triazole-resistant A. fumigatus (TRAF) harbouring the G54E mutation from environmental samples in India, Romania and Tanzania. This mutation in the cyp51A azole target gene of A. fumigatus is so far considered as de novo occurring in patients due to prolonged exposure to azoles. A total of 81 soil and woody debris samples from India, Romania and Tanzania were processed for detection of TRAF and determination of their susceptibility to medical triazoles and fungicides. cyp51A sequencing and real-time PCR were performed for detection of mutations. The isolates were genotyped by microsatellite typing. Overall, 25% of samples (20/81) from India, Romania and Tanzania harboured TRAF. Of the 20 samples harbouring TRAF, a single resistance mechanism, the G54E mutation, was found in 16 samples from three countries. This mechanism was responsible for 46.4% of resistant isolates from Tanzania, 30.4% from Romania and 20.0% from India. The G54E isolates revealed high MICs of itraconazole and posaconazole and were cross-resistant to agricultural fungicides. The majority of the Romanian and Tanzanian G54E isolates had an identical genotype. The present report describes the genetic heterogeneity of TRAF strains harbouring the G54E mutation in the environment of India, Romania and Tanzania. It may be anticipated that long-term exposure of A. fumigatus to fungicides may induce selection of G54 mutants in the environment.
在接受长期唑类治疗的慢性肺病患者中,烟曲霉的三唑耐药性会产生,或者通过对耐药烟曲霉的环境选择而产生。在此,我们首次报告从印度、罗马尼亚和坦桑尼亚的环境样本中分离出携带G54E突变的三唑耐药烟曲霉(TRAF)。烟曲霉cyp51A唑类靶基因中的这种突变迄今为止被认为是患者因长期接触唑类而从头发生的。对来自印度、罗马尼亚和坦桑尼亚的总共81份土壤和木质碎片样本进行了处理,以检测TRAF并确定它们对医用三唑类药物和杀菌剂的敏感性。进行了cyp51A测序和实时PCR以检测突变。通过微卫星分型对分离株进行基因分型。总体而言,来自印度、罗马尼亚和坦桑尼亚的样本中有25%(20/81)含有TRAF。在这20份含有TRAF的样本中,在来自三个国家的16份样本中发现了单一耐药机制,即G54E突变。该机制导致坦桑尼亚46.4%的耐药分离株、罗马尼亚30.4%的耐药分离株和印度20.0%的耐药分离株产生耐药。携带G54E突变的分离株显示出较高的伊曲康唑和泊沙康唑最低抑菌浓度,并且对农用杀菌剂具有交叉耐药性。大多数罗马尼亚和坦桑尼亚携带G54E突变的分离株具有相同的基因型。本报告描述了在印度、罗马尼亚和坦桑尼亚环境中携带G54E突变的TRAF菌株的遗传异质性。可以预期,烟曲霉长期接触杀菌剂可能会在环境中诱导G54突变体的选择。